证券代码：688067 证券简称：爱威科技 公告编号：2025-043 （一）审议通过《关于公司 2025 年第三季度报告的议案》 具体内容请详见公司同日刊载于上海证券交易所网站（www.sse.com.cn）的 《爱威科技股份有限公司 2025 年第三季度报告》。本议案已经公司董事会审计委 员会审议通过。 表决情况：7 票同意，0 票反对，0 票弃权。 （二）审议通过《关于公司 2025 年前三季度利润分配方案的议案》 具体内容请详见公司同日刊载于上海证券交易所网站（www.sse.com.cn）的 《爱威科技股份有限公司关于公司 2025 年前三季度利润分配方案的公告》。本议 案已经公司董事会审计委员会审议通过。 爱威科技股份有限公司 第五届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会召开情况 爱威科技股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日召开第 五届董事会第六次会议。本次会议以现场结合通讯方式召开,会议应出席董事 7 人，实际出席董事 7 人,会议 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、利润分配方案内容 公司 2024 年年度股东大会审议通过了《关于公司 2025 年中期分红安排的议 案》，同意公司可于 2025 年中期（包含半年度、前三季度），在报告期当期盈利、 母公司报表中累计未分配利润为正、公司现金流可以满足正常经营和持续发展需 求，并且符合《公司章程》规定的其他利润分配条件的前提下，进行现金分红， 分红总额不超过相应期间归属于公司股东的净利润。 根据公司 2025 年第三季度报告（未经审计），2025 年前三季度合并报表归 属于母公司股东净利润为 29,237,454.88 元，截至 2025 年 9 月 30 日，母公司期 末可供分配的利润为 159,350,241.45 元。结合公司发展规划和经营情况，经董 1 ● 每股分配比例：每 10 股派发现金红利 0.54 元（含税），不进行资本公 积金转增股本，不送红股。 ● 本次利润分配以实施权益分派股权登记日登记的总股本扣除公司回购专 用账户持有公司股份后的股本总额为基数，具体 ...

Core Viewpoint - Aivi Technology (688067.SH) reported a revenue of 61.38 million yuan in the third quarter, reflecting a year-on-year growth of 9.76% [1] - The net profit attributable to shareholders reached 15.18 million yuan, marking a year-on-year increase of 12.22% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 13.86 million yuan, showing a year-on-year growth of 16.35% [1] - The basic earnings per share stood at 0.22 yuan [1]

Financial Performance - The company's revenue for Q3 2025 reached ¥61,380,846.02, representing a year-on-year increase of 9.76%[4] - The total profit for the period was ¥16,866,463.98, reflecting a growth of 12.23% compared to the same period last year[4] - Net profit attributable to shareholders was ¥15,182,079.94, up by 12.22% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥13,864,264.03, which is a 16.35% increase from the previous year[4] - The basic earnings per share for the quarter was ¥0.22, marking a 10.00% increase compared to the same period last year[5] - Total operating revenue for the first three quarters of 2025 reached ¥170,924,204.46, an increase of 11.8% compared to ¥153,120,219.59 in the same period of 2024[19] - Net profit for the first three quarters of 2025 was ¥29,237,454.88, representing a 16.8% increase from ¥25,129,248.58 in the same period of 2024[20] - Basic and diluted earnings per share for the first three quarters of 2025 were both ¥0.43, compared to ¥0.37 in 2024, indicating a growth of 16.2%[21] Research and Development - Research and development expenses totaled ¥6,207,331.35, accounting for 10.11% of revenue, a decrease of 0.51 percentage points year-on-year[5] - Research and development expenses for the first three quarters of 2025 totaled ¥16,901,751.79, slightly up from ¥16,336,278.27 in 2024[19] Assets and Liabilities - The company's total assets increased to ¥611,460,889.24, representing a growth of 9.00% from the end of the previous year[5] - Total current assets increased to ¥419,311,574.22 from ¥305,417,272.07, representing a growth of approximately 37.2%[15] - Total liabilities increased to ¥93,091,918.82 from ¥65,152,523.33, indicating a rise of about 42.9%[16] - The total assets of the company reached ¥611,460,889.24, up from ¥560,997,764.86, showing an increase of approximately 9.0%[15] - The company’s inventory increased to ¥47,582,320.33 from ¥45,678,062.27, reflecting a growth of about 4.2%[15] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥28,488,492.57, showing a significant increase of 212.67%[9] - Net cash flow from operating activities amounted to $28,488,492.57, a significant increase from $9,111,460.86 in the previous period, reflecting improved operational efficiency[26] - Total cash inflow from investment activities reached $681,970,309.94, compared to $273,664,909.05 in the prior period, indicating a strong investment performance[26] - Cash outflow from investment activities was $718,748,773.19, up from $318,146,250.45, resulting in a net cash flow from investment activities of -$36,778,463.25, an improvement from -$44,481,341.40[26] - Cash inflow from financing activities totaled $29,801,750.00, with cash outflow amounting to $6,727,800.00, leading to a net cash flow from financing activities of $23,073,950.00, a recovery from -$15,455,934.18[27] - The company's cash and cash equivalents increased by $14,764,164.25, contrasting with a decrease of $50,835,755.33 in the previous period, indicating a positive liquidity position[27] - The ending balance of cash and cash equivalents stood at $68,486,613.35, significantly higher than $31,964,454.62 at the end of the previous period, showcasing improved cash management[27] - The company reported a total cash outflow related to operating activities of $176,047,833.33, compared to $163,114,539.17 previously, reflecting increased operational costs[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 4,350[11] - The largest shareholder, Ding Jianwen, holds 25,997,143 shares, representing 38.23% of the total shares[11] - The number of shares held by the company's repurchase account is 722,000, accounting for 1.06% of the total share capital[12] - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[12] Other Financial Metrics - The weighted average return on equity rose to 2.97%, an increase of 0.26 percentage points compared to the previous year[5] - The company reported a total of ¥1,317,815.91 in non-recurring gains for the period, with a year-to-date total of ¥3,988,600.19[8] - Other income for the first three quarters of 2025 was ¥5,614,372.44, down from ¥6,172,313.49 in 2024[19] - The company reported a decrease in investment income to ¥4,092,051.99 from ¥5,245,393.22 in the previous year[20] Accounting Standards - The company implemented adjustments in accounting standards effective January 1, 2024, impacting prior period financials[22] - The company has not yet adopted new accounting standards effective from 2025, indicating a stable accounting framework for the current reporting period[28]

爱威科技股份有限公司 子公司管理制度 第一章 总则 第一条 为了规范爱威科技股份有限公司(以下简称"公司"或"母公司") 控股子公司(以下简称"子公司")经营管理行为，促进子公司健康发展，优化公 司资源配置，提高子公司的经营积极性和创造性，依照《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》《上海证券交易所科 创板股票上市规则》（以下简称"《上市规则》"）、《上海证券交易所科创板 上市公司自律监管指引第 1 号——规范运作》（以下简称"《自律监管指引》"） 等法律、行政法规、部门规章、规范性文件以及《爱威科技股份有限公司章程》 （以下简称"《公司章程》"）等，特制定本制度。 第三条 公司与子公司之间是平等的法人关系。母公司以其持有的股权数 额，依法对子公司享有资产收益、参与重大决策、选择管理者等股东权利。 加强对子公司的管理，旨在建立有效的控制机制，对子公司的组织、资源、 资产、投资和公司的运作、财务、风险等进行全方位管控，确保子公司业务符合 公司总体发展战略，规范运作，避免潜在风险。 第四条 子公司具有法人资格，依法独立承担民事责任，依法享有法人财产 权，以其法人财产自主经营， ...

Group 1 - The core transaction on October 28 involved 120,000 shares of Aiwei Technology, with a transaction value of 3.2424 million yuan, at a price of 27.02 yuan, representing a discount of 4.49% compared to the closing price [2][4] - Over the past three months, Aiwei Technology has recorded a total of 7 block trades, amounting to 25.176 million yuan [3] - The stock closed at 28.29 yuan on the same day, with a daily turnover rate of 2.02% and a total trading volume of 38.509 million yuan, while experiencing a net outflow of 1.6462 million yuan in main funds [3] Group 2 - The latest margin financing balance for Aiwei Technology is 43.7447 million yuan, showing a decrease of 1.4264 million yuan, or 3.16%, over the past five days [4] - Aiwei Technology was established on March 16, 2000, with a registered capital of 68 million yuan [4]

Core Insights - The medical device sector experienced a slight increase of 0.37% on October 24, with Mai Lande leading the gains [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Medical Device Sector Performance - Top gainers included: - Mai Lande (688273) with a closing price of 41.92, up 6.31%, trading volume of 29,300 hands, and a transaction value of 121 million yuan [1] - Xiangyu Medical (688626) at 53.21, up 6.10%, with a trading volume of 41,100 hands and a transaction value of 216 million yuan [1] - Xiangsheng Medical (688358) at 35.27, up 4.75%, with a trading volume of 38,400 hands and a transaction value of 136 million yuan [1] - Other notable gainers included: - Aohua Endoscopy (688212) at 50.59, up 4.74%, with a transaction value of 225 million yuan [1] - Weisi Medical (688580) at 49.10, up 4.71%, with a transaction value of approximately 99.8 million yuan [1] Decliners in Medical Device Sector - Notable decliners included: - Chenguang Medical (920300) at 17.51, down 8.80%, with a trading volume of 124,000 hands [2] - Toukeng Life (300642) at 22.95, down 5.40%, with a trading volume of 175,700 hands [2] - Haitai New Light (688677) at 48.50, down 5.05%, with a trading volume of 38,800 hands [2] - Other significant decliners included: - Sino Medical (688108) at 28.00, down 4.73%, with a trading volume of 263,700 hands [2] - Tianchen Medical (688013) at 55.66, down 3.98%, with a trading volume of 19,200 hands [2] Capital Flow in Medical Device Sector - The medical device sector saw a net outflow of 654 million yuan from major funds, while retail investors contributed a net inflow of 455 million yuan [2]

Core Viewpoint - The company, Awei Technology Co., Ltd., is making a strategic investment of 10 million RMB in Hunan Luying Technology Co., Ltd., acquiring a 9.0744% stake, which aligns with its long-term development goals and aims to enhance its competitive edge in the medical imaging sector [2][13][14]. Investment Overview - The total investment amount for this round is 30 million RMB, with Awei Technology contributing 10 million RMB to subscribe for 249.3766 thousand RMB of the new registered capital of Luying Technology [4][8]. - The investment does not require board or shareholder approval as it falls within the general manager's authority and has completed internal decision-making processes [5][14]. Target Company Information - Hunan Luying Technology Co., Ltd. specializes in the development of high-resolution single-photon emission computed tomography (SPECT) and its core components, aiming to provide advanced molecular imaging diagnostic solutions [6][13]. - The company was established less than a year ago and currently does not have any sales revenue or profit [6][16]. Market Context - The global medical imaging and radiation therapy equipment market is experiencing rapid and stable growth, with significant government support for the domestic nuclear medicine industry, particularly in promoting the localization of nuclear medicine imaging equipment [13][14]. - SPECT/CT technology is recognized for its clinical value in early cancer diagnosis and has a strong market outlook, making it a strategic area for investment [13][14]. Strategic Implications - This investment is expected to deepen synergies within the company's main business and enhance its overall competitiveness, aligning with its strategic development plans [13][14]. - The funding for this investment comes from the company's own resources and will not adversely affect its normal operations or financial status [14]. Future Considerations - The success of this investment will depend on Luying Technology's future operational performance and its ability to navigate various risks associated with market conditions, technology development, and regulatory approvals [16].

Policy Developments - The National Medical Products Administration (NMPA) is enhancing support for medical device research and innovation, aiming to improve the efficiency of review and approval processes, and accelerate the market entry of innovative products [2] Company Announcements - SanegeneBio's SGB-9768, a targeted C3 siRNA drug, has received Orphan Drug Designation from the FDA for treating C3 glomerulopathy, with a promising subcutaneous administration regimen [4] - Meikang Bio has obtained three medical device registration certificates for in vitro diagnostic reagents, which will enhance its product line and market competitiveness [5] - Meihua Medical reported a 19.25% decline in net profit for the first three quarters of 2025, despite a 3.28% increase in revenue [7] - China National Pharmaceutical Group (Sinopharm) reported a 13.10% increase in net profit for the third quarter of 2025, with a revenue growth of 3.58% [8] - Aiwai Technology announced a 10 million yuan investment in Luying Technology, acquiring a 9.07% stake, although Luying is still in the development phase with no sales revenue [10] - Yingke Medical's subsidiary plans to invest 70 million USD in a fund with a target size of 17 billion USD [12] Industry Developments - A breakthrough in oral insulin delivery has been achieved by a team from Beihang University, significantly improving the bioavailability of oral insulin to 20.4%, which is over 20 times that of traditional formulations [14] - Science Corporation has developed a retinal microchip implant that restores vision to blind patients, allowing them to read and engage in activities like crossword puzzles [15] - In the first eight months of this year, Beijing's medical instrument and device exports reached 5.83 billion yuan, a 21.5% increase year-on-year [16]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688067 证券简称：爱威科技 公告编号：2025-042 爱威科技股份有限公司关于与专业投资机构共同投资湖南麓影科技有限公司的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示: ● 投资标的名称： 湖南麓影科技有限公司（以下简称"麓影科技"或"标的公司"） ● 投资金额：爱威科技股份有限公司（以下简称"公司"）以自有资金出资人民币1,000万元对麓影科技进 行增资。增资完成后，公司将持有麓影科技9.0744%的股权。 ● 根据《上海证券交易所科创板股票上市规则》《公司章程》及相关制度的规定，本次对外投资在公司 总经理审批权限内，并已履行内部决策程序，无需提交董事会、股东大会审议。 ● 本次对外投资不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规定的重大资产重组情 形。 ● 相关风险提示 1、公司已与共同增资方、麓影科技及其现有股东签署了增资协议，麓影科技尚需按照法律法规的规定 办理工商变更等相关变更登记手续。 2、本次投资完成 ...